Focus: Catalent is a large Contract Development and Manufacturing Organization (CDMO) headquartered in Somerset, NJ, serving pharma and biotech clients globally with 10,001–50,000 employees. As a public company (CTLT), it operates across multiple therapeutic areas with a focus on manufacturing, quality assurance, and clinical supply capabilities.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
Hot — 610 jobs added in 30d
Net +327 (610 new, 283 removed). Aggressive expansion phase.
3 recent layoff filings (12 mo) — 8 affected
Source: state DOL filings via Big Local News
Catalent offers solid manufacturing operations and technical careers in a stable CDMO, but recent layoffs and shallow pipeline suggest career risk in specialized roles; best suited for manufacturing, QA, and supply-chain professionals seeking large-scale operational experience.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generic antihistamine indicating Catalent's footprint in mature, low-margin commoditized generics rather than branded innovation.
Help build intelligence for Catalent
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Catalent's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Post-LOE NSAID reinforcing focus on established generic manufacturing with limited commercial growth upside.
Generic antihistamine in a crowded, mature market; exemplifies Catalent's role as a CDMO rather than innovator.
Generic anti-seizure medication indicating Catalent's manufacturing expertise in CNS generics post-patent expiration.
1 discontinued, 0 duplicate formulations not shown
Catalent to sell UK facility to Codis in spray drying expansion - megaproject.com
Catalent to sell UK facility to Codis in spray drying expansion megaproject.com
Catalent sells UK facility to Codis; expands partnership with Nanoscope Therapeutics - Fierce Pharma
Catalent sells UK facility to Codis; expands partnership with Nanoscope Therapeutics Fierce Pharma
Codis Acquiring Catalent’s Nottingham UK Facility - Pulse 2.0
Codis Acquiring Catalent’s Nottingham UK Facility Pulse 2.0
The Changing Reality of Pharmaceutical Commercialization | PharmExec - Pharmaceutical Executive
The Changing Reality of Pharmaceutical Commercialization | PharmExec Pharmaceutical Executive
Codis To Acquire Catalent's Nottingham, UK Facility to Create Europe's Leading End-to-End Spray Dry Capability - PR Newswire
Codis To Acquire Catalent's Nottingham, UK Facility to Create Europe's Leading End-to-End Spray Dry Capability PR Newswire
Rezon Bio adds Catalent veteran to commercial team - The Pharma Letter
Rezon Bio adds Catalent veteran to commercial team The Pharma Letter
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Leveraging analytical and bioprocess platforms for biological product development and commercialization - A meeting report.
Validated GMP banking of a new set of genomically stable induced pluripotent stem cell lines using single-cell passaging.
Source: state DOL filings, aggregated via Big Local News
Significant recent layoff activity (574+ employees across 18+ months) signals active workforce optimization; interview discussions should clarify role permanence and team stability post-restructuring.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo